Trials / Completed
CompletedNCT01518920
A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-04958242 In Subjects With Age-Related Sensorineural Hearing Loss
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.
Detailed description
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04958242 | PF-04958242 0.35 mg oral solution |
| DRUG | PF-04958242 | PF-04958242 0.27 mg oral solution |
| DRUG | Placebo | Placebo oral solution |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2012-01-26
- Last updated
- 2019-11-21
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01518920. Inclusion in this directory is not an endorsement.